Kronos Bio is a biopharmaceutical company that is advancing two investigational compounds in clinical trials for patients with cancer.

Source: https://www.marketscreener.com/quote/stock/KRONOS-BIO-INC-113534496/news/Kronos-Bio-To-Present-Positive-Preliminary-Data-from-Phase-1-Dose-Escalation-Portion-of-Ongoing-Phas-45172152/?utm_medium=RSS&utm_content=20231027

Tarlatamab is an investigational, targeted therapy engineered by Amgen researchers that brings a patient's own T cells in close proximity to SCLC cells by binding both CD3 on T cells and DLL3 on SCLC cells.

Source: https://www.marketscreener.com/quote/stock/AMGEN-INC-4847/news/FDA-Grants-Priority-Review-to-Amgen-s-Tarlatamab-Application-for-Advanced-Small-Cell-Lung-Cancer-45563652/?utm_medium=RSS&utm_content=20231213

Teropavimab and zinlirvimab are investigational compounds and are not approved by the U.S. Food and Drug Administration or any other regulatory authority for any use.

Source: https://www.ibtimes.com.au/press-release/20230720/gilead-showcases-latest-hiv-pipeline-progress-and-the-impact-of-global-collaboration-on-health-equity-efforts-at-ias-2023

This release discusses investigational uses of an agent in development and is not intended to convey conclusions about efficacy or safety.

Source: https://www.prnewswire.com/news-releases/bioarctics-partner-eisai-submits-marketing-authorization-application-for-lecanemab-as-treatment-for-early-alzheimers-disease-in-japan-301722047.html

We anticipate that our investigational drug will show antidepressant effect in PTSD compared to placebo and we hope that it will demonstrate specific effect out of fear memory component of PTSD and directly reduce symptoms of PTSD itself.

Source: https://seekingalpha.com/article/4591405-nrx-pharmaceuticals-inc-nrxp-q4-2022-earnings-call-transcript?source=feed_all_articles